Donate
info@cureduchenne.org(949) 872-2552
EventsContact
Cart
×

No products in the cart.

CureDuchenne
Moble Nav Icon
  • Cure
    • Research Overview
    • Research Terms
    • Exon Skipping
    • Clinical Trials
  • Care
    • COVID-19 Resources
    • Newly Diagnosed
    • Clinics
    • Steroid Use
    • Emergency Care
    • Resource Library
    • DME Guide
    • Medical ID Bracelets
    • Navigating School
    • Occupational Therapy
    • Physical Therapy
    • For Families
    • - Find a Physical Therapist
    • - Pool Activities
    • - Stretching
    • For Physical Therapists
    • - PT Certification
    • - Professional Courses
    • For Clinics
  • Community
    • CureDuchenne CARES
    • CureDuchenne FUTURES
    • CureDuchenne Champions
    • Family Stories
    • Events
    • Previous Webinars
    • Family Fundraisers
  • About Us
    • Mission
    • Vision
    • About Duchenne
    • Blog
    • Board of Directors
    • Sponsors
    • Reports and Financials
    • Events & Webinars
    • News Center
    • - Press Releases
    • - Research
  • CD Ventures
    • About CD Ventures
    • Our Impact
  • Get Involved
    • Donate
    • More Ways to Give
    • Fundraise
    • Shop
    • Fundraising Events
    • - Ladies Luncheon Austin
    • - CureDuchenne Golf Shootout | Orange County, CA
    • - Napa in Newport | Orange County, CA
  • Donate
  • All
  • Cure Duchenne Blog
  • Press Releases
  • CureDuchenne In The News
  • Research

FDA declines to approve Capricor’s deramiocel for the treatment of Duchenne

November 20, 2026

Despite recognition of the tremendous unmet medical need in Duchenne muscular dystrophy, the FDA has decided that the evidence is not sufficient to approve Capricor’s deramiocel for the treatment of […]

Read More

Servier ends clinical trials for sevasemten in both Becker and Duchenne muscular dystrophy

November 13, 2026

After the recent and disappointing news that the GRAND CANYON study in Becker muscular dystrophy did not meet its primary or key secondary endpoints, and a Governance Committee review of […]

Read More

Satellos Phase 2 trial in boys with Duchenne will use MRI-measured fat fraction as primary efficacy endpoint

November 6, 2026

Satellos Bioscience, which received prior funding from CureDuchenne, has announced that after meeting with the FDA they have amended the primary endpoint in their Phase 2 BASECAMP trial to now […]

Read More

Capricor’s PDUFA date for FDA to review Deramiocel has been extended to November 22, 2026

August 24, 2026

Capricor Therapeutics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy […]

Read More

Precision BioSciences has dosed the first individual with their novel gene editing approach for individuals with Duchenne mutations between exons 45 and 55

August 24, 2026

Precision BioSciences has shared that the first participant in the FUNCTION_DMD clinical trial has received their investigational gene editing treatment, PBGENE-DMD.  PBGENE-DMD delivers ARCUS nucleases via AAV9 to cut out […]

Read More

The FDA will review Dyne’s application for Accelerated Approval of z-rostudirsen for skipping exon 51

July 20, 2026

FDA Will Review Dyne Application for Skipping Exon 51 CureDuchenne was an early funder of Dyne Therapeutics, and we are pleased to share that the FDA has accepted the BLA […]

Read More

Italfarmaco reports positive data from the EPIDYS trial and its ongoing open-label extension of givinostat in Duchenne

July 8, 2026

Italfarmaco reported new data from the Phase 3 EPIDYS trial, showing that quantitative MRI measures of muscle mass and fat fraction were significantly different between the treatment and placebo groups.  […]

Read More

Satellos reports positive interim data from adults treated with SAT-3247

July 8, 2026
CureDuchenne was an early funder of Satellos, and we are pleased to share that they have reported 6-month interim data from 4 individuals (aged 21-28) treated with SAT-3247.  These individuals [...]
Read More

FDA accepts Sarepta’s application to convert AMONDYS 45 and VYONDYS 53 from accelerated to full approval

June 30, 2026

Proposed text:  CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to share that the US FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 […]

Read More
  • 1
  • 2
  • 3
  • 4
  • Next Page »
  • About

    • Mission
    • About Duchenne MD
    • Blog
    • Store
    • News Center
  • Get Involved

    • Donate
    • Fundraising
    • Attend an Event
  • CureDuchenne

    • 100 Bayview Circle, Suite 5600
      Newport Beach, CA 92660
      (949) 872-2552
      info@cureduchenne.org

  • Get Connected

  • Charity Navigator Four-Star Charity
  • Candid Platinum Transparency Seal

PRIVACY POLICY | TERMS OF USE | INDIRECT COST POLICY | TAX INFO

CureDuchenne is a 501c3 registered tax-exempt nonprofit organization. Federal Tax ID: #20-0299958 | ©2026 CureDuchenne. All rights reserved.

Please be advised that the contents within the CureDuchenne site include a compilation of articles, advisements, and references from the community. CureDuchenne does not provide medical advice nor is CureDuchenne a medical provider. The intent of this shared content is to serve as a point of reference for informational purposes. Please refer to your health care provider(s) for your individualized, specific care management needs. The CureDuchenne website may contain links to external websites that are not provided and/or maintained by or in any way affiliated with CureDuchenne. CureDuchenne recommends that you review the terms of service and privacy policies of these external websites before entering. Please note that CureDuchenne does not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.